NPPA fixes prices of 22 drug formulations

The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 22 formulations used for treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.

While National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations, it has also capped the ceiling prices of two formulations, a notification on the regulator’s website said.

The prices have been fixed/revised under the Drug (Prices Control) Order, 2013, it added.

The regulator has fixed ceiling prices of Co-trimoxazole (Sulphamethoxazole(A) and Trimethoprim(B) tablets used for treating a variety of bacterial infections and oral rehydration salt (ORS).

It has also fixed the retail prices of drugs manufactured and marketed by various firms such as Omeprazole Domperidone capsule used for treatment of acidity and gastroesophageal reflux disease, Clotrimazole Beclomethasone cream used for treating variety of inflamed fungal skin infections.

The regulator has also fixed the retail price of Rosuvastatin Clopidogrel tablet used to lower cholesterol level and triglycerides and Tenofovir Disoproxil Fumarate Lamividine Efavirenz tablet used in treatment of HIV, among others.

The NPPA is mandated to fix/revise the prices of controlled bulk drugs and formulations and to enforce prices and availability of the medicines in the country.

It also monitors the prices of decontrolled drugs in order to keep them at reasonable levels.

The regulator implements and enforces the provisions of the Drugs (Prices Control) Order.

It is also entrusted with the task of recovering amounts overcharged by manufacturers for the controlled drugs from the consumers.

  • Related Posts

    • Pharma
    • June 27, 2025
    • 132 views
    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

    • Pharma
    • June 27, 2025
    • 119 views
    Sun Pharma ropes in Richard Ascroft as North America CEO

    Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    MedTech Zone AMTZ Puts Vizag on the Science Map of India

    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

    Sun Pharma ropes in Richard Ascroft as North America CEO

    Sun Pharma ropes in Richard Ascroft as North America CEO

    Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

    Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen